Overview
- 7 inspections across 6 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-01-09.
At a glance
Inspections
7
Sites
6
Observations
0
Career since
Jan 2023
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| QOL Medical LLC | 9 Jan 2026 | Human Drugs | On file |
| GlaxoSmithKline LLC | 25 Sep 2024 | Human Drugs | On file |
| Lonza Biologics, Inc. | 12 Jul 2024 | Human Drugs | On file |
| PCI San Diego, Inc. | 20 Sep 2023 | Human Drugs | On file |
| Genentech, Inc. | 2 Feb 2023 | Human Drugs | On file |
Sites inspected
QOL Medical LLCClearwater, United States1 insp.
GlaxoSmithKline LLCConshohocken, United States1 insp.
Lonza Biologics, Inc.Portsmouth, United States1 insp.
PCI San Diego, Inc.San Diego, United States1 insp.
Genentech, Inc.South San Francisco, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Michael Shanks4 shared
Zhong Li2 shared
Hirdesh Kumar1 shared
Kayla V Sprague1 shared
Jee Y Chung1 shared
Saundrea A Munroe1 shared
Cassandra L Abellard1 shared
Bryan A Galvez1 shared
Christopher R Czajka1 shared
Nayan J Patel1 shared
Full investigator report
Get the verbatim findings behind Yi Wang's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site